Sugar chain-related gene and use thereof
AssigneeStelic Institute & Co.
InventorsHiroyuki Yoneyama, Jun Koyama, Masato Fujii
Life of this patent
Estimating the term…
Abstract
As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).
Claims13
A method of treating a fibrogenic disorder, the method comprising:
- identifying a subject having a fibrogenic disorder of a tissue selected from the group consisting of cardiac tissue, gastrointestinal tissue, lung tissue, pancreatic tissue, kidney tissue, ocular tissue, cranial nerve tissue, and skin tissue;
- and
- administering to the subject a therapeutically effective amount of an siRNA that suppresses expression of a gene encoding a sulfotransferase that transfers a sulfate to position 4 or 6 of N-acetylgalactosamine;
- wherein the siRNA suppresses expression of a nucleotide sequence selected from the group consisting of a GalNAc4S-6ST gene, a GalNAc4ST-1 gene, a GalNAc4ST-2 gene, a C4ST-1 gene, a C4ST-2 gene, a C4ST-3 gene, a C6ST-1 gene, a C6ST-2 gene, and a D4ST gene.
A tissue fibrogenesis suppressing-agent, comprising:
- an inhibitor of sulfation at position 4 or 6 of N-acetylgalactosamine,
- wherein the inhibitor is an siRNA that suppresses expression of the GalNAc4S-6ST gene,
- wherein the siRNA comprises the nucleotide sequences of SEQ ID NO:
- 25 and SEQ ID NO:
- 26.
A siRNA comprising the nucleotide sequences of SEQ ID NO:
- 25 and SEQ ID NO:
- 26.
A method of treating a fibrogenic disorder, the method comprising:
- identifying a subject having a fibrogenic disorder of a tissue selected from the group consisting of cardiac tissue, gastrointestinal tissue, lung tissue, pancreatic tissue, kidney tissue, ocular tissue, cranial nerve tissue, and skin tissue;
- and
- administering to the subject a therapeutically effective amount of an siRNA that suppresses expression of a gene encoding a sulfotransferase that transfers a sulfate to position 4 or 6 of N-acetylgalactosamine;
- wherein the siRNA suppresses expression a GalNAc4S-6ST gene, and
- wherein the siRNA comprises the nucleotide sequences of SEQ ID NO:
- 25 and SEQ ID NO:
- 26.
Dependencies are inferred from the claim text.